Oxford's Covid-19 vaccine India trial: Serum Institute asked to modify protocol

Oxford's Covid-19 vaccine India trial: Serum Institute asked to modify protocol

Brazil's Covid-19 outbreak, the world's worst outside the United States, has made it global testing ground for potential vaccines.

SII Chief Executive Officer Adar Poonawalla told PTI, "It is too early to comment on the vaccine's price. Russian Federation will have got there first", said Kirill Dmitriev, the head of RDIF, in an interview with CNN.

"We want to cover the whole world, " Soriot said, "so everyone can get access to this vaccine".

The investigational vaccine in question (mRNA-1273) is developed by Modern Inc., a biotechnological company based in Cambridge, Massachusetts, along with the National Institute of Allergy and Infectious Diseases (NIAID).

The vaccine, MRNA-1273, given to non-human primates protected against infection in the lungs and nose, and prevented pulmonary disease in all animals, the company said in a news release.

"This scientifically rigorous, randomized, placebo-controlled trial is created to determine if the vaccine can prevent COVID-19 and for how long such protection may last", Fauci said, the news release indicated.

In a separate development, Moderna's vaccine candidate has been found to produce encouraging results in a trial that inoculated 16 monkeys.

The adenoviral vector-based vaccine developed by Russian military and government researchers is now in phase 2 trials. The United States is helping bankroll several vaccine candidates under its Operation Warp Speed program.

German companies are developing "promising" coronavirus vaccine candidates, but it might take until the middle of 2021 for one of them to be widely available to the public, German Research Minister Anja Karliczek said Wednesday.

Dozens of vaccine trials are underway around the world and a small number are in large-scale efficacy trials, but most developers have cautioned that much work remains before their vaccines can be approved.

Vaccinated macaques produced high levels of neutralising antibodies directed at the surface spike protein used by SARS-CoV-2 to attach to and enter cells, the researchers said.

"This means that there are 24 vaccine candidates in the clinical trial stage are in phase I, II or III done on human volunteers at multi-centric sites".

Balram Bhargava, Director General of Indian Medical Research Institute (ICMR), talked about the four challenges that will arise after a safe and effective vaccine is developed.

Those who complete the study will receive $1,000.

Earlier this month, the Kremlin denied allegations Russian spies hacked into American, Canadian and British research labs to steal vaccine development secrets.

Related Articles